After participating
in this activity, participants should be able to:
 | Illustrate the importance of IV iron and EPO
in effective anemia treatment | | Describe the benefits of IV iron therapy
independent of EPO therapy | | Summarize the current iron markers used to
determine iron status |
|
Discuss K/DOQI recommendations for treating
iron-deficient patients based on serum ferritin levels |
|
Describe the clinical implications of an elevated
serum ferritin level |
Rajiv Agarwal, MD
Associate Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana
Daniel Coyne, MD
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri
| |
 |
|
ACCREDITATION / DESIGNATION
STATEMENT(S) : |
This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the sponsorship of the Medical Education Resources, Inc.
Medical Education Resources, Inc. is accredited by the ACCME to sponsor
continuing medical education for physicians and takes responsibility for the content,
quality, and scientific integrity of this CME activity.
Medical Education
Resources, Inc. designates this educational activity for a maximum of 1.5 hours
in Category 1 credit toward the AMA Physician's Recognition Award. Each physician
should claim only those hours of credit that he/she actually spent in the educational
activity.
| INSTRUCTIONS FOR CME CREDIT : |
|
Post-test and Evaluation Form are at this link, but you must listen to all four talks from this symposium prior to completing the test. |
|
To earn CME credit
for viewing the lectures, please print and complete the CME Posttest questions
and return with the completed Evaluation Form to Medical Education Resources,
Inc. via fax at (303) 798-5731 or mail at 1500 West Canal Court, Suite 500, Littleton,
Colorado 80120-5617.
|
This program is intended for clinicians who work in the area of nephrology.
|
FACULTY DISCLOSURE STATEMENTS : |
All
faculty participating in continuing medical education programs are expected to
disclose to the program audience any real or apparent conflict of interest related
to the subject under discussion. The faculty disclosure information is as follows:
Rajiv Agarwal, MD, has received grant/research support from Watson Pharma, Inc. and is a consultant, Speakers Bureau participant, and Advisory Board member for Watson Pharma, Inc.
Daniel Coyne, MD, has received grant/research support from Watson Pharma, Inc. and is a consultant and Speakers Bureau participant for Watson Pharma, Inc.
| DISCLOSURE OF UNLABELED USE RRI/HDCN (if applicable): |
This educational
activity contains discussion of published and/or investigational uses of agents
that are not indicated by FDA. Medical Education Resources, RRI, HDCN do
not recommend the use of any agent outside of the labeled indications. Please
refer to the official prescribing information for each product for discussion
of approved indications, contraindications and warnings.
All
of the agents overviewed in this virtual symposium will be discussed in the context
of uses for which they have not been approved by the FDA. | |
